Clinical management of adult sickle-cell disease

Current Opinion in Hematology

Volumn 19, Issue 3, 2012, Pages 149-155

  Bartolucci, Pablo ^a,b,c   Galactéros, Frédéric ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITÉ DE LILLE   (France)

^c UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

acute; chronic; clinical management; sickle cell; treatment

Indexed keywords

BOSENTAN; EPHEDRINE; ETILEFRINE; HYDROXYUREA; PLACEBO; SENICAPOC; SILDENAFIL; THEOPHYLLINE;

ACUTE CHEST SYNDROME; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AVASCULAR NECROSIS; BLOOD FLOW VELOCITY; BLOOD VESSEL OCCLUSION; DOPPLER ECHOGRAPHY; DRUG SAFETY; ECHOCARDIOGRAPHY; HUMAN; KIDNEY DYSFUNCTION; NONHUMAN; OXYGEN THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIAPISM; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETINA INJURY; REVIEW; SICKLE CELL ANEMIA; SKIN ULCER; SPIROMETRY; STROKE;

ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; HUMANS; HYDROXYUREA; HYPERTENSION, PULMONARY; KIDNEY DISEASES; SKIN DISEASES; STROKE;

EID: 84859870595     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e328351c35f     Document Type: Review

References (83)

1. Perronne V, Roberts-Harewood M, Bachir D, et al. Patterns of mortality in sickle cell disease in adults in France and England. Hematol J 2002; 3:56-60. (Pubitemid 34223917)
2. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330:1639-1644.
3. Kaul DK, Fabry ME, Nagel RL. Vaso-occlusion by sickle cells: evidence for selective trapping of dense red cells. Blood 1986; 68:1162-1166. (Pubitemid 17186396)
4. Kaul DK, Fabry ME, Windisch P, et al. Erythrocytes in sickle cell anemia are heterogeneous in their rheological and hemodynamic characteristics. J Clin Invest 1983; 72:22-31. (Pubitemid 13026625)
5. Mozzarelli A, Hofrichter J, Eaton WA. Delay time of hemoglobin S polymerization prevents most cells from sickling in vivo. Science 1987; 237:500-506. (Pubitemid 17125918)
6. Eaton WA, Hofrichter J, Ross PD. Delay time of gelation: a possible determinant of clinical severity in sickle cell disease [editorial]. Blood 1976; 47:621-627.
7. Clark MR, Mohandas N, Shohet SB. Deformability of oxygenated irreversibly sickled cells. J Clin Invest 1980; 65:189-196. (Pubitemid 10214346)
8. Allon M. Renal abnormalities in sickle cell disease. Arch Intern Med 1990; 150:501-504. (Pubitemid 20122000)
9. Rothstein M, Obialo C, Hruska KA. Renal tubular acidosis. Endocrinol Metab Clin North Am 1990; 19:869-887.
10. Bellet PS, Kalinyak KA, Shukla R, et al. Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases. N Engl J Med 1995; 333:699-703.
11. Brugnara C. Erythrocyte dehydration in pathophysiology and treatment of sickle cell disease. Curr Opin Hematol 1995; 2:132-138.
12. Eaton WA, Hofrichter J. Hemoglobin S gelation and sickle cell disease. Blood 1987; 70:1245-1266. (Pubitemid 18026123)
13. Ataga KI, Smith WR, De Castro LM, et al. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood 2008; 111:3991-3997.
14. Rivera A, Ferreira A, Bertoni D, et al. Abnormal regulation of Mg2 + transport via Na/Mg exchanger in sickle erythrocytes. Blood 2005; 105:382-386. (Pubitemid 40053108)
15. De Franceschi L, Bachir D, Galacté ros F, et al. Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. J Clin Invest 1997; 100:1847-1852. (Pubitemid 27431344)
16. Messmann R, Gannon S, Sarnaik S, Johnson RM. Mechanical properties of sickle cell membranes. Blood 1990; 75:1711-1717. (Pubitemid 20145761)
17. Franco RS, Yasin Z, Lohmann JM, et al. The survival characteristics of dense sickle cells. Blood 2000; 96:3610-3617.
18. Gupta VL, Chaubey BS. Efficacy of zinc therapy in prevention of crisis in sickle cell anemia: a double blind, randomized controlled clinical trial. J Assoc Physicians India 1995; 43:467-469.
19. Ataga KI, Reid M, Ballas SK, et al. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043). Br J Haematol 2011; 153:92-104.
20. Hankins JS, Wynn LW, Brugnara C, et al. Phase I study of magnesium pidolate in combination with hydroxycarbamide for children with sickle cell anaemia. Br J Haematol 2008; 140:80-85. (Pubitemid 350233253)
21. Wang W, Brugnara C, Snyder C, et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multicentre CHAMPS trial. Br J Haematol 2011; 152:771-776.
22. Haute Autorité de Santé . Long term disease n8 10: sickle cell disease in adults. French guidelines; 2010.
23. Lionnet F, Arlet J-B, Bartolucci P, et al. Guidelines for management of adult sickle cell disease. Rev Méd Interne 2009; 30 (Suppl 3):S162-S223.
24. Rees DC, Olujohungbe AD, Parker NE, et al. Guidelines for the management of the acute painful crisis in sickle cell disease. Br J Haematol 2003; 120: 744-752. (Pubitemid 36315093)
25. The management of sickle cell disease. National Heart, Lung, and Blood Institute (NHLBI) produced publications; 2004. NIH publication 02-2117.
26. Uzun B, Kekec Z, Gurkan E. Efficacy of tramadol vs meperidine in vasoocclusive sickle cell crisis. Am J Emerg Med 2010; 28:445-449.
27. Bartolucci P, El Murr T, Roudot-Thoraval F, et al. A randomized, controlled clinical trial of ketoprofen for sickle-cell disease vaso-occlusive crises in adults. Blood 2009; 114:3742-3747.
28. Gladwin MT, Kato GJ, Weiner D, et al. Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. JAMA 2011; 305:893-902.
29. Machado RF, Barst RJ, Yovetich NA, et al. Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood 2011; 118:855-864.
30. Styles LA, Schalkwijk CG, Aarsman AJ, et al. Phospholipase A2 levels in acute chest syndrome of sickle cell disease. Blood 1996; 87:2573-2578. (Pubitemid 26086904)
31. Styles LA, Aarsman AJ, Vichinsky EP, Kuypers FA. Secretory phospholipase A2 predicts impending acute chest syndrome in sickle cell disease. Blood 2000; 96:3276-3278.
32. Styles LA, Abboud M, Larkin S, et al. Transfusion prevents acute chest syndrome predicted by elevated secretory phospholipase A2. Br J Haematol 2007; 136:343-344. (Pubitemid 46020766)
33. Dessap AM, Deux J-F, Abidi N, et al. Pulmonary artery thrombosis during acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med 2011; 184:1022-1029.
34. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med 1995; 332:1317-1322.
35. Stallworth JR, Jerrell JM, Tripathi A. Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. Am J Hematol 2010; 85:795-797.
36. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 2003; 289:1645-1651. (Pubitemid 37430269)
37. McGann PT, Ware RE. Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? Curr Opin Hematol 2011; 18:158-165.
38. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood 2010; 115:2354-2363.
39. Platt OS. Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med 2008; 358:1362-1369.
40. Paule I, Sassi H, Habibi A, et al. Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen. Orphanet J Rare Dis 2011; 6:30.
41. Bachir D, Hulin A, Huet E, et al. Plasma and urine hydroxyurea levels might be useful in the management of adult sickle cell disease. Hemoglobin 2007; 31:417-425. (Pubitemid 350125631)
42. Steinberg MH, Lu ZH, Barton FB, et al. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter study of hydroxyurea. Blood 1997; 89:1078-1088. (Pubitemid 27121303)
43. Styles LA, Lubin B, Vichinsky E, et al. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea. Blood 1997; 89:2554-2559. (Pubitemid 27143305)
44. Bartolucci P, Chaar V, Picot J, et al. Decreased sickle red blood cell adhesion to laminin by hydroxyurea is associated with inhibition of Lu/BCAM protein phosphorylation. Blood 2010; 116:2152-2159.
45. Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of longterm use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol 2010; 85:403-408.
46. Nzouakou R, Bachir D, Lavaud A, et al. Clinical follow-up of hydroxyureatreated adults with sickle cell disease. Acta Haematol 2011; 125:145-152.
47. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (Baby Hug). Lancet 2011; 377:1663-1672.
48. Shelby MD. NTP-CERHR expert panel report on the reproductive and developmental toxicity of hydroxyurea. Research Triangle Park, NC: National Toxicology Program; 2007.
49. Flanagan JM, Howard TA, Mortier N, et al. Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia. Mutat Res 2010; 698:38-42.
50. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998; 91:288-294. (Pubitemid 28018756)
51. Adams RJ, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 2005; 353:2769-2778. (Pubitemid 43016816)
52. Gyang E, Yeom K, Hoppe C, et al. Effect of chronic red cell transfusion therapy on vasculopathies and silent infarcts in patients with sickle cell disease. Am J Hematol 2011; 86:104-106.
53. Hulbert ML, McKinstry RC, Lacey JL, et al. Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood 2011; 117:772-779.
54. Bernaudin F, Verlhac S, Arnaud C, et al. Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort. Blood 2011; 117:1130-1140.
55. Bernaudin F, Verlhac S, Cöc L, et al. Long-term follow-up of pediatric sickle cell disease patients with abnormal high velocities on transcranial Doppler. Pediatr Radiol 2005; 35:242-248. (Pubitemid 40425047)
56. Ware RE, Schultz WH, Yovetich N, et al. Stroke with transfusions changing to hydroxyurea (SWITCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatr Blood Cancer 2011; 57:1011-1017.
57. Panepinto JA, Walters MC, Carreras J, et al. Matched-related donor transplantation for sickle cell disease: report from the center for international blood and transplant research. Br J Haematol 2007; 137:479-485. (Pubitemid 46698289)
58. Walters MC, Sullivan KM, Bernaudin F, et al. Neurologic complications after allogeneic marrow transplantation for sickle cell anemia. Blood 1995; 85:879-884.
59. Parent F, Bachir D, Inamo J, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med 2011; 365:44-53.
60. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.NEngl JMed 2004; 350:886-895. (Pubitemid 38252536)
61. Machado RF, Hildesheim M, Mendelsohn L, et al. NT-Pro brain natriuretic peptide levels and the risk of death in the cooperative study of sickle cell disease. Br J Haematol 2011; 154:512-520.
62. Ataga KI, Moore CG, Jones S, et al. Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br J Haematol 2006; 134:109-115. (Pubitemid 43830036)
63. De Castro LM, Jonassaint JC, Graham FL, et al. Pulmonary hypertension associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes. Am J Hematol 2008; 83:19-25.
64. Barst RJ, Mubarak KK, Machado RF, et al. Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the asset studies. Br J Haematol 2010; 149:426-435.
65. Haymann J-P, Stankovic K, Levy P, et al. Glomerular hyperfiltration in adult sickle cell anemia: a frequent hemolysis associated feature. Clin J Am Soc Nephrol 2010; 5:756-761.
66. Day TG, Drasar ER, Fulford T, et al. Association between hemolysis and albuminuria in adults with sickle cell anemia. Haematologica 2011; 97:201-205.
67. Falk RJ, Scheinman J, Phillips G, et al. Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme. N Engl J Med 1992; 326:910-915.
68. Powars DR, Chan LS, Hiti A, et al. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore) 2005; 84:363-376. (Pubitemid 41668935)
69. Taylor JG 6th, Nolan VG, Mendelsohn L, et al. Chronic hyper-hemolysis in sickle cell anemia: association of vascular complications and mortality with less frequent vasoocclusive pain. PLoS ONE 2008; 3:e2095.
70. Kato GJ, McGowan V, Machado RF, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 2006; 107:2279-2285. (Pubitemid 43345545)
71. Mi T, Abbasi S, Zhang H, et al. Excess adenosine in murine penile erectile tissues contributes to priapism via A2b adenosine receptor signaling. J Clin Invest 2008; 118:1491-1501. (Pubitemid 351500442)
72. Zhang Y, Dai Y, Wen J, et al. Detrimental effects of adenosine signaling in sickle cell disease. Nat Med 2011; 17:79-86.
73. Kato GJ. Priapism in sickle-cell disease: a hematologist's perspective. J Sex Med 2012; 9:70-78.
74. Olujohungbe AB, Adeyoju A, Yardumian A, et al. A prospective diary study of stuttering priapism in adolescents and young men with sickle cell anemia: report of an international randomized control trial: the Priapism in sickle Cell Study. J Androl 2011; 32:375-382.
75. McMahon L, Tamary H, Askin M, et al. A randomized phase II trial of arginine butyrate with standard local therapy in refractory sickle cell leg ulcers. Br J Haematol 2010; 151:516-524.
76. Leveziel N, Bastuji-Garin S, Lalloum F, et al. Clinical and laboratory factors associated with the severity of proliferative sickle cell retinopathy in patients with sickle cell hemoglobin C (SC) and homozygous sickle cell (SS) disease. Medicine (Baltimore) 2011; 90:372-378.
77. Hernigou P, Daltro G, Filippini P, et al. Percutaneous implantation of autologous bone marrow osteoprogenitor cells as treatment of bone avascular necrosis related to sickle cell disease. Open Orthop J 2008; 2:62-65.
78. Hernigou P, Habibi A, Bachir D, Galacté ros F. The natural history of asymptomatic osteonecrosis of the femoral head in adults with sickle cell disease. J Bone Joint Surg Am 2006; 88:2565-2572. (Pubitemid 44901942)
79. Hernigou P, Zilber S, Filippini P, et al. Total THA in adult osteonecrosis related to sickle cell disease. Clin Orthop Relat Res 2008; 466:300-308. (Pubitemid 351912914)
80. Walters MC, Patience M, Leisenring W, et al. Bone marrow transplantation for sickle cell disease. N Engl J Med 1996; 335:369-376. (Pubitemid 26257244)
81. Hsieh MM, Kang EM, Fitzhugh CD, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med 2009; 361:2309-2317.
82. Bernaudin F, Socié G, Kuentz M, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood 2007; 110:2749-2756. (Pubitemid 47523201)
83. Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human b-thalassaemia. Nature 2010; 467:318-322.